Peter M. Ravdin
The University of Texas MD Anderson Cancer Center · 163 works · 28,385 citations · h-index 58
Top works
- The Decrease in Breast-Cancer Incidence in 2003 in the United States
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
- Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
- Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Lateral motion of fluorescently labeled acetylcholine receptors in membranes of developing muscle fibers.
- Ki67 in breast cancer: prognostic and predictive potential
- HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
- Fluorescent tetramethyl rhodamine derivatives of α-bungarotoxin: Preparation, separation, and characterization
- Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
- Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.